GW-501516 vs RAD-140 for weight loss
Short answer: For weight loss, more users report improvement with RAD-140 — 92% of 51 reports, versus 86% of 50 for GW-501516.
GW-501516 has 0 meta-analyses and 0 randomized trials on PubMed; RAD-140 has 0 and 0.
Based on 307 reports about GW-501516 and 677 about RAD-140. Not medical advice.
| GW-501516 Substance | RAD-140 SARM | |
|---|---|---|
| User score | 46 | 44 |
| Verdict | Mostly positive | Mixed |
| Positive of reports that state an outcome | 64% | 42% |
| Reports | 307 | 677 |
| Research | DResearch: None | DResearch: None |
| Meta-analyses / RCTs | 0 / 0 | 0 / 0 |
| Mainly used for | ||
| Weight loss % reporting improvement | 86% (50) | 92% (51) |
| Appetite % reporting improvement | 50% (4) | 56% (9) |
| Focus % reporting improvement | — | 17% (6) |
| Energy % reporting improvement | 95% (19) | 41% (51) |
| Sleep % reporting improvement | 0% (2) | 3% (39) |
| Anxiety % reporting improvement | — | 7% (15) |
| Mood % reporting improvement | 100% (2) | 37% (52) |
| Memory % reporting improvement | — | 100% (2) |
| Performance % reporting improvement | 93% (71) | 93% (292) |
| Recovery % reporting improvement | 100% (3) | 100% (26) |
| Pain & inflammation % reporting improvement | — | 17% (12) |
| Digestion % reporting improvement | — | 0% (3) |
| Libido % reporting improvement | — | 42% (38) |
| Hormones % reporting improvement | — | 5% (62) |
| Heart & lipids % reporting improvement | 89% (19) | 6% (32) |
| Skin & hair % reporting improvement | — | 0% (11) |
| Longevity % reporting improvement | 50% (2) | — |
| Common side effects | cancer risk, acne, fatigue, brain fog | suppression, hair loss, fatigue, insomnia |
| Typical dose reported | 20 mg | Not listed |
RAD-140Full RAD-140 profile →
What a user said
“I had my hopes up for RAD-140 and it is still too early to tell but I think we're moving in the right direction.”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate